Healio column
Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.
Initially, ART consisted of complex regimens with high daily pill burdens. Today, ART regimens are highly efficacious and well tolerated, consisting mostly of one multidrug pill taken once per day. However, obstacles persist for people living with HIV. Adherence to daily oral ART can be a challenge because of factors such as pill fatigue, mental health issues, substance use disorders, unstable housing and the stigma associated with taking daily pills.
Over the past few years, several long-acting agents have become available, transforming both HIV treatment and prevention.
A column in Healio discusses the long-acting medications currently available, and their role in HIV treatment and pre-exposure prophylaxis.
Read the full column here.
Source : Healio
Related HIV and Co-Infections News
-
[Statement] MSF: Gilead stockholders: Demand Gilead sell HIV prevention drug to those who need it
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
AVAC: New PEPFAR data reveal a prevention crisis beneath the surface
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.